The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
|Videos|January 5, 2023
Zanubrutinib Demonstrates Superior Progression-Free Survival Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Results from Final Analysis of ALPINE Randomized Phase 3 Study
Author(s)Nicole Lamanna, MD
Nicole Lamanna, MD, reviews the results of the phase 3 study evaluating the use of zanubrutinib versus ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Advertisement
Advertisement
Related to this article
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Advertisement
Advertisement
Trending on OncLive
1
Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer
2
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer
3
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC
4
Ad Hoc Analysis Supports Contributions of Both Enfortumab Vedotin and Pembrolizumab in Cisplatin-Ineligible MIBC
5